文献
J-GLOBAL ID:201802260143395014
整理番号:18A0844645
免疫チェックポイント阻害剤療法を受ける非小細胞肺癌患者の選択のためのクローン22C3 PHARMDXキットを用いたPD-L1試験:細胞学的細胞は生存可能な選択を阻止する【JST・京大機械翻訳】
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
著者 (6件):
Torous Vanda F.
(Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts)
,
Rangachari Deepa
(Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts)
,
Gallant Benjamin P.
(Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts)
,
Shea Meghan
(Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts)
,
Costa Daniel B.
(Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts)
,
VanderLaan Paul A.
(Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts)
資料名:
Journal of the American Society of Cytopathology
(Journal of the American Society of Cytopathology)
巻:
7
号:
3
ページ:
133-141
発行年:
2018年
JST資料番号:
W2955A
ISSN:
2213-2945
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)